Anavex Life Sciences (AVXL) Long-Term Deferred Tax (2023 - 2025)

Anavex Life Sciences' Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $20.7 million for Q3 2025.

• In Q3 2025, Long-Term Deferred Tax rose 37.09% year-over-year to $20.7 million; the TTM figure through Sep 2025 stood at $20.7 million (up 37.09% YoY), while the FY2025 annual figure was $20.7 million, up 37.09% from the prior year.
• Long-Term Deferred Tax came in at $20.7 million for Q3 2025 at Anavex Life Sciences, up from $15.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $20.7 million in Q3 2025 to a low of $7.2 million in Q3 2023.
• A 3-year average of $14.3 million and a median of $15.1 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax soared 109.72% in 2024 and surged 37.09% in 2025, its largest moves.
• Anavex Life Sciences' Long-Term Deferred Tax stood at $7.2 million in 2023, then jumped by 109.72% to $15.1 million in 2024, then soared by 37.09% to $20.7 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $20.7 million, $15.1 million, and $7.2 million for Q3 2025, Q3 2024, and Q3 2023 respectively.

Peer Comparison